Fredun Pharmaceuticals Limited announces Q2 & H1 FY2026 unaudited results and NSE listing plan
Fredun Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited financial results for quarter and half-year ended 30th Sept 2026 on 05 Nov 2026
- Limited Review Reports by R.H. Nisar & Co. issued with no material misstatement noted
- Board approved application for listing equity shares on National Stock Exchange of India Limited (NSE) subject to approvals
Why it's rated notable: The quarterly results were declared but the filing states no profit or revenue figures for the quarter or the year-earlier quarter, so no year-on-year change can be computed and the level stays at medium, while the NSE listing is a proposal subject to approvals.
Original filing
Revised Outcome Of The Board Meeting
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Fredun Pharmaceuticals
- Acquisition / mergerNotableFredun Pharmaceuticals Ltd. acquires pet-wellness brand Furlicks from USV & Wellbeing Nutrition
Other financial results filings this fortnight
- B.R.Goyal Infrastructure Ltd announces unaudited half-year financials and approvals
- Rashi Peripherals Limited approves ₹900 crore equity fundraise and board changes
- Welspun Enterprises reports Q2 & H1 FY27 standalone and consolidated results
- Scan Steels approves results for quarter and half year ended September 30, 2026
- Hindustan Composites appoints Vinay Sarin CEO; approves Sept 2026 quarter results
- Scan Steels approves Q2 and H1 results to Sep 30, 2026 and NSE direct listing proposal
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.